Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Phase 4
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Registration Number
- JPRN-jRCT1080222006
- Lead Sponsor
- Eisai Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Patients were eligible for inclusion in the study if they had a smoking history, a diagnosis of COPD, %FEV1< 80% and a ratio of FEV1 to forced vital capacity(FVC) of < 70%, and a documented history of at least one exacerbation leading to any treatment within the previous year.
Exclusion Criteria
Patients with egg allergy
Patients with domiciliary oxygen therapy
Patients with pneumonia or pulmonary tuberculosis
Patients with severe cardiovascular disorder, severe kidney disorder, severe hepatic disorder, severe hematological disorder
Patients with cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy<br>Exacerbation of chronic obstructive pulmonary disease
- Secondary Outcome Measures
Name Time Method